ABSTRACT Background Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality, and many high‐risk patients fail to reach LDL‐cholesterol (LDL‐C) targets on statins alone. Evolocumab, a PCSK9 inhibitor, offers potent LDL‐C lowering, but a synthesis of its lipid and clinical benefits in seconda...
Anika Goel, M. Naveed, H. Tandel et al.· Endocrinology, Diabetes & Me...· 0 citations
Obesity is projected to affect about one billion adults by 2030 and is associated with cardiometabolic morbidity. Orforglipron is an oral, non-peptide glucagon-like peptide-1 receptor agonist developed to provide weight and metabolic benefits. Prior meta-analyses have supported its efficacy and safety but were limited...
Mohamed Gamal Hegaz, Mohammad Yassin Al Aboud, Abanoub I. I. Kamel et al.· BMC Endocrine Disorders· 0 citations
Findings strengthen the evidence for selective aldosterone synthase inhibition as a therapeutic approach for aldosterone-mediated hypertension and suggest that baxdrostat may provide an additional treatment option, particularly for patients who remain uncontrolled or cannot tolerate mineralocorticoid receptor antagonis...
Muhammad Burhan, Z. Shahid, M. Naveed et al.· The Annals of Pharmacotherap...· 0 citations
Patients with T2DM undergoing TAVR demonstrate higher risks of all‐cause mortality, MACCE, and HF exacerbation compared to their counterparts without T2DM.
The T2DM cohort also demonstrated higher all‐cause readmissions, mechanical ventilation, and renal replacement therapy compared to patients without T2D...
Hritvik Jain, Nandan Patel, M. Naveed et al.· Catheterization and cardiova...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
